The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
Figure 5
Effects of imatinib on breast cancer cell survival and ERK1/2 phosphorylation in response to CSF-1.
24 hours serum deprived SKBR3 or MDAMB468 cells were treated for 45 minutes with (light gray columns, right pictures) or without (dark gray columns, left pictures) 10 µM imatinib (IM) and then with 25 ng/ml CSF-1 for (A) 48 hours or (B) 10 minutes. (A) Cells were scored for cell viability by crystal violet staining. Data represent percentages (± SEM) of crystal violet staining normalized for IM-untreated cells from 4 independent experiments; *, Student's t test: p<0.05. (B) Cells were lysed and protein lysates subjected to immunoblotting with the indicated antibodies. Densitometric values of bands (normalized for loading control) are reported as ratios between treated and untreated value, set as 1.